What is TYRA's current stock price?

TYRA (Tyra Biosciences, Inc.) is currently trading at $32.47 with a market cap of $1.93B.

What sector is Tyra Biosciences, Inc. in?

Tyra Biosciences, Inc. (TYRA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TYRA a good stock to buy?

Analysts have a Buy consensus on TYRA with a price target of $50.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TYRA Tyra Biosciences, Inc.

Healthcare

$32.47-1.67%ClosedMarket Cap: $1.93B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.17

P/S

0.00

EV/EBITDA

-13.29

DCF Value

$1.18

FCF Yield

-5.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-42.7%

ROA

-31.8%

ROIC

-36.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-39.3M	$—
Q4 null	$0.00	$-33.8M	$—
FY null	$0.00	$-119.9M	$—
Q3 null	$0.00	$-29.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$50.50

Target (Median)

$51.50

Target Range

$42.00 - $59.00

2 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-05-14

Piper SandlerOverweight

2026-03-20

HC Wainwright & Co.Buy

2026-02-17

WedbushOutperform

2026-02-13

OppenheimerOutperform

2026-02-03

Trading Activity

Insider Trades

View All

Warner Douglas Jofficer: Chief Medical Officer

SellThu May 07

Warner Douglas Jofficer: Chief Medical Officer

SellThu May 07

Rueb Yuliyaofficer: Vice President, Finance (PAO)

SellThu May 07

Rueb Yuliyaofficer: Vice President, Finance (PAO)

SellThu May 07

Harris Todddirector, officer: President and CEO

SellThu May 07

Latest News

Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha · Wed May 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.79

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Peers